← Back to patent-cliff list
FG-001
Tier C — Watch / tradeFG-001
FluoGuide AS
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
In vivo diagnostic
Type
Targets：PLAUR
Indications (approved)：高级别胶质瘤, 低级别胶质瘤, Glioma, Meningioma, 脑癌, Head and neck cancer, Lung cancer
Regional status
US
Phase II
2026-06-30
EU
Phase II
2022-03-01
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of FG-001?
Approved indications include: 高级别胶质瘤, 低级别胶质瘤, Glioma, Meningioma, 脑癌, Head and neck cancer, Lung cancer.
When does the FG-001 patent expire?
No public expiry year is available for FG-001 yet; this page updates once verified.
How do I get a quote for FG-001 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-05